BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:37 PM
 | 
Jul 24, 2009
 |  BC Extra  |  Company News

Negative opinions for Lyrica, Impulsor, Erbitux

EMEA's CHMP issued several negative opinions on Friday, including recommending against approval of two fibromyalgia treatments marketed in the U.S. On reexamination, the agency reaffirmed its April negative opinion for Lyrica pregabalin from Pfizer Inc. (NYSE:PFE). The committee said the benefits of the drug in the indication had not been shown...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >